INTRODUCTION

The definition of sepsis has recently changed to include sequential organ failure assessment (SOFA) and quick SOFA (qSOFA) criteria, with an emphasis on organ failure [1, 2]. The SOFA grade requires a complete assessment of numerous laboratory variables (a ratio of arterial oxygen partial pressure to fractional inspired oxygen platelets, bilirubin, mean arterial pressure, creatinine/urine output) and the Glasgow coma scale score. In contrast, qSOFA only requires three clinical criteria (respiratory rate, altered mentation, and systolic blood pressure) and can be applied as a rapid bedside screening tool. However, systemic inflammatory response syndrome (SIRS) remains an essential component in the diagnosis of sepsis [3], and the measurement of biomarkers to detect exacerbations in inflammatory conditions could be helpful. Procalcitonin (PCT) is known to exhibit the highest accuracy among the many biomarkers of sepsis [4]. In this study, we evaluated the diagnostic performance of PCT and qSOFA in combination, namely PCT–qSOFA, to propose a simpler and more accurate method of diagnosing sepsis.

MATERIALS AND METHODS

1. Study population

Subjects who ordered more than two consecutive requests for
blood culture (BC), owing to a suspicion of sepsis, and PCT at the same time between May 2016 and April 2017 were included in this study. Bloodstream infections due to *Staphylococcus aureus*, *Enterococcus spp.*, *Klebsiella pneumoniae*, and *Escherichia coli* were included. The exclusion criteria were age < 18 years, duplicate cases, and inadequate data for calculating SIRS or qSOFA scores.

The study population consisted of 102 patients with laboratory-confirmed primary bloodstream infection [5] and 102 patients with repeated negative BC results. The criteria for laboratory-confirmed primary bloodstream infection were that the patient must have a recognized pathogen in one or more BCs and the organism cultured from the blood should not be related to an infection at another site. The recognized pathogens included *S. aureus*, *Enterococcus spp.*, *E. coli*, *Pseudomonas spp.*, *Klebsiella spp.*, *Candida spp.*, and others.

The 204 patients were subdivided into four groups on the basis of BC results and SIRS scores (≥ 2/4): the bacterial sepsis group (group 1, N = 67), BC-negative sepsis group (group 2, N = 37), BC-positive group without corresponding clinical symptoms or signs of sepsis (group 3, N = 55), and the control group without evidence of sepsis (group 4, N = 65). The main interest of this study was to determine whether patients outside the intensive care unit (ICU) as well as in the ICU can benefit from PCT and qSOFA assessment. Therefore, qSOFA scores were also divided into four groups, including and excluding patients in the ICU (N = 23), in all the analyses.

This study was approved by the Institutional Review Board of National Health Insurance Service Ilsan Hospital (NHIMC 2018-05-014).

2. Laboratory diagnosis

BC was performed using BacT/ALERT FA/NA (bioMérieux, Marcy l’Etoile, France). Species identification and antimicrobial susceptibility testing were performed using the MALDI Biotyper system (Brucker Daltonics, Bremen, Germany) and Microscan WalkAway (Siemens Healthcare Diagnostics, Deerfield, IL, USA), respectively. PCT was measured using a chemiluminescence immunoassay (ADVIA Centaur, Siemens, Erlangen, Germany). Samples above the measurement range (0.02–75.00 µg/L) were diluted.

3. Review of clinical data

The total study population was subdivided into four groups based on BC results and SIRS scores. SIRS was scored for the day blood cultures were ordered by retrospectively reviewing electronic medical records. The criteria for SIRS were the presence of two or more of the following: temperature > 38°C or < 36°C, heart rate > 90 beats/min, respiratory rate > 20 breaths/min or a ratio of arterial oxygen partial pressure to fractional inspired oxygen < 32 mmHg, white blood cell count >12,000/mm³ or < 4,000/mm³, and immature bands >10% [6]. The criteria for qSOFA were respiratory rate ≥ 22 breaths/min, altered mentation (Glasgow coma scale score < 15), and systolic blood pressure ≤ 100 mmHg [1]. We also obtained data such as age, sex, acquisition type, ICU admission, emergency room admission, diagnosis, previous antimicrobial use in the last seven days, prognosis, microbiology culture results, white blood cell count, mental status, Glasgow coma scale score, and vital signs. Mental status was categorized into three groups: alert, nearly alert–very drowsy, and stupor–coma. The mental status of “alert” was assigned when a patient could follow commands in a timely fashion. Stuporous patients required vigorous stimulation, and comatose patients could not respond appropriately to verbal or painful stimuli. All the other patients were categorized into the nearly alert–very drowsy group.

4. Statistical analysis

Blood PCT levels and qSOFA scores were compared among the four groups using one-way ANOVA followed by the Bonferroni post hoc test.

The Youden index, a summary of the receiver operating characteristic (ROC) curve analysis, was estimated to evaluate the diagnostic performance with logistic regression and area under the ROC (AUROC) curves. We used logistic regression analysis with the presence of sepsis as the binary dependent variable and PCT levels and qSOFA scores as predictor variables to calculate the predicted probability value of the combination of the two markers. This predicted probability value was also used to calculate the AUROC value for the combination of the two markers. Differences between the AUROCs were compared using the Delong method.

Post-test probability and post-test odds were analyzed to determine whether PCT–qSOFA improves the diagnostic value [7]. We included group 3 in the sepsis group (groups 1, 2, and 3) in the post-test probability analysis. Group 3 corresponded to bloodstream infection according to the CDC standard [5], and sepsis could not be completely excluded even though the criteria for SIRS were
Table 1. Demographic and clinical characteristics of the subjects

| Parameters                                      | Group 1* (N = 67) | Group 2† (N = 37) | Group 3‡ (N = 35) | Group 4§ (N = 65) |
|------------------------------------------------|-------------------|-------------------|-------------------|-------------------|
| Age (yr) Median (IQR)                          | 73.0 (62.7 to 81.8) | 75.0 (53.7 to 83.3) | 77.0 (71.0 to 81.8) | 74.0 (63.3 to 82.0) |
| Sex (N, %)                                      |                   |                   |                   |                   |
| Male                                           | 29 (43.3)         | 20 (54.1)         | 21 (60.0)         | 37 (56.9)         |
| Female                                         | 38 (56.7)         | 17 (45.9)         | 14 (40.0)         | 28 (43.1)         |
| ICU admission (N, %)                            |                   |                   |                   |                   |
| Yes                                            | 7 (10.4)          | 5 (13.5)          | 5 (14.3)          | 6 (9.1)           |
| No                                             | 60 (89.6)         | 32 (86.5)         | 30 (85.7)         | 60 (90.9)         |
| ER admission (N, %)                            |                   |                   |                   |                   |
| Yes                                            | 31 (46.3)         | 18 (48.6)         | 18 (51.4)         | 43 (66.2)         |
| No                                             | 36 (53.7)         | 19 (51.4)         | 17 (48.6)         | 22 (33.8)         |
| Admission diagnosis (N, %)                     |                   |                   |                   |                   |
| Gastrointestinal disease                       | 17 (25.4)         | 6 (16.2)          | 5 (14.3)          | 14 (21.5)         |
| Cerebrovascular disease                        | 1 (1.5)           | 3 (8.1)           | 0 (0.0)           | 5 (7.7)           |
| Diabetes mellitus                              | 0 (0.0)           | 2 (5.4)           | 3 (8.6)           | 1 (1.5)           |
| Renal disease                                  | 17 (25.4)         | 3 (8.1)           | 14 (40.0)         | 9 (13.8)          |
| Pulmonary disease                              | 7 (10.4)          | 12 (32.4)         | 6 (17.1)          | 18 (27.7)         |
| Cardiovascular disease                         | 7 (10.4)          | 3 (8.1)           | 2 (5.7)           | 9 (13.8)          |
| Rheumatic disease                              | 0 (0.0)           | 1 (2.7)           | 0 (0.0)           | 0 (0.0)           |
| Hematologic malignancy                         | 2 (3.0)           | 0 (0.0)           | 1 (2.9)           | 1 (1.5)           |
| Solid tumor                                    | 6 (9.0)           | 2 (5.4)           | 2 (5.7)           | 4 (6.2)           |
| Others                                         | 10 (14.9)         | 5 (13.5)          | 2 (5.7)           | 4 (6.2)           |
| Previous antibiotics (<7 days) (N, %)           |                   |                   |                   |                   |
| Yes                                            | 24 (35.8)         | 6 (16.2)          | 10 (28.6)         | 4 (6.2)           |
| No                                             | 43 (64.2)         | 31 (83.8)         | 25 (71.4)         | 61 (93.8)         |
| Prognosis (N, %)                               |                   |                   |                   |                   |
| Survival                                       | 45 (67.2)         | 31 (83.8)         | 29 (82.9)         | 59 (90.8)         |
| 90 day-mortality                               | 22 (32.8)         | 6 (16.2)          | 6 (17.1)          | 6 (9.2)           |
| Infection source (N, %)                        |                   |                   |                   |                   |
| Blood                                          | 67 (100.0)        | 0 (0.0)           | 35 (100.0)        | 0 (0.0)           |
| Urine                                          | 0 (0.0)           | 5 (13.5)          | 0 (0.0)           | 10 (15.4)         |
| Sputum                                         | 0 (0.0)           | 4 (10.8)          | 0 (0.0)           | 4 (6.2)           |
| Wound                                          | 0 (0.0)           | 2 (5.4)           | 0 (0.0)           | 0 (0.0)           |
| Pleural                                        | 0 (0.0)           | 1 (2.7)           | 0 (0.0)           | 0 (0.0)           |
| Bile                                           | 0 (0.0)           | 1 (2.7)           | 0 (0.0)           | 1 (1.5)           |
| Microbiology (N, %)                             |                   |                   |                   |                   |
| *S. aureus*                                    | 21 (31.3)         | 3 (8.1)           | 7 (20.0)          | 4 (6.2)           |
| *E. faecalis*                                  | 7 (10.4)          | 1 (2.7)           | 5 (14.3)          | 1 (1.5)           |
| *E. faecium*                                   | 4 (6.0)           | 0 (0.0)           | 1 (2.9)           | 0 (0.0)           |
| *K. pneumoniae*                                | 10 (14.9)         | 3 (8.1)           | 6 (17.1)          | 3 (4.6)           |
| *E. coli*                                      | 25 (37.3)         | 4 (10.8)          | 16 (45.7)         | 4 (6.2)           |
| Others†                                         | 0 (0.0)           | 2 (5.4)           | 0 (0.0)           | 3 (4.6)           |
| Polymicrobial BSI (N, %)                       |                   |                   |                   |                   |
| Yes                                            | 10 (14.9)         | 0 (0.0)           | 3 (8.6)           | 0 (0.0)           |
| No                                             | 57 (85.1)         | 37 (100.0)        | 32 (91.4)         | 65 (100.0)        |

*Group 1, bacterial sepsis (BSI+SIRS+); † Group 2, blood culture-negative sepsis (BSI-SIRS+); ‡ Group 3, blood culture-positive without clinical symptoms (BSI-SIRS-); § Group 4, control (BSI-SIRs-); † Others comprised * S. agalactiae (N = 1), coagulase-negative staphylococci (N = 1), Bacteroides spp. (N = 1), and * P. mirabilis (N = 2). Abbreviations: BC, blood culture; N, number; IQR, interquartile range; ICU, intensive care unit; ER, emergency room; SIRS, systemic inflammatory response syndrome; BSI, bloodstream infection.
Fig. 1. Difference of procalcitoin and qSOFA score median values and the Mann–Whitney comparison of the four groups: (A) Procalcitonin, (B) qSOFA, (C) qSOFA in subjects outside the ICU.

*Group 1, bacterial sepsis (BSI+SIRS+); †Group 2, blood culture-negative sepsis (BSI-SIRS+); ‡Group 3, blood culture-positive without clinical symptoms (BSI+SIRS-); §Group 4, control (BSI-SIRS-).

Abbreviations: PCT, procalcitonin; qSOFA, quick sequential organ failure assessment; BSI, bloodstream infection; SIRS, systemic inflammatory response syndrome; ICU, intensive care unit; SD, standard deviation; IQR, interquartile range (25th percentile to 75th percentile).
were not met. Not all patients with SIRS are septic, and there are subgroups of hospitalized patients, particularly at extremes of age, who do not meet the criteria for SIRS on presentation but who progress to multiple organ dysfunction [8].

Comparisons of SIRS and qSOFA scores in concordant and discordant groups were performed using the Mann–Whitney U test for continuous variables and the chi-square test for categorical variables. We used SAS software version 9.4 (SAS Institute, Cary, NC, USA), MedCalc version 19.4.1 (MedCalc, Mariakerke, Belgium) and Analyse-it Method Validation Edition software, version 4.60.4 (Analyse-it Software Ltd, City West Business Park, Leeds, UK) for the statistical analyses. P values less than 0.05 were considered significant.

RESULTS

1. Characteristics of the study population

The characteristics of bacterial sepsis group (group 1, N = 67), BC-negative sepsis group (group 2, N = 37), BC-positive group without corresponding clinical symptoms or signs of sepsis (group 3, N = 35), and the control group without evidence of sepsis (group 4, N = 65) are summarized in Table 1.

2. Comparisons of PCT and qSOFA scores in the four groups

PCT levels did not significantly differ between the four groups. The mean ± standard deviations were 16.17 ± 36.60 in group 1, 3.36 ± 9.58 in group 2, 16.45 ± 57.26 in group 3, and 6.61 ± 29.35 in group 4 (P = 0.0963). In all the patients, the qSOFA scores of groups 1 and 2 were significantly different from those of group 4 (P = 0.0031 for group 1 vs. group 4 and P = 0.0068 for group 2 vs. group 4) (Fig. 1). When patients in the ICU were excluded, the qSOFA scores of groups 1 and 2 were also significantly different from those of group 4 (P = 0.0279 for group 1 vs. group 4 and P = 0.0048 for group 2 vs. group 4). Group 2 vs. group 3 qSOFA scores were also significantly different (P = 0.0251) when patients in the ICU were excluded.

3. Diagnostic performance of PCT and qSOFA

We applied various PCT cutoff values to identify a better AUROC. In the ROC analysis, the AUROC of PCT (cutoff of >2.47 μg/L), qSOFA (cutoff of ≥1), and qSOFA (cutoff of ≥2) excluding patients in the ICU was 0.701, 0.628, and 0.610, respectively (Fig. 2).

![Fig. 2. Receiver operating characteristic curve comparison of PCT and qSOFA in sepsis. AUROC values are shown in parentheses. Abbreviations: PCT, procalcitonin; qSOFA, quick sequential organ failure assessment; ex. ICU, excluding subjects in the ICU; AUROC, area under the receiver operating characteristics curve.](https://doi.org/10.47429/lmo.2021.11.1.32)
The AUROCs of PCT (cutoff of > 0.18 μg/L) and qSOFA (cutoff of ≥ 1) of patients in the ICU were 0.765 and 0.725, respectively. The combination of PCT and qSOFA showed improved diagnostic performance when compared with the qSOFA score alone. The AUROC of PCT–qSOFA was 0.718 (all subjects), 0.714 (excluding subjects in the ICU, Fig. 2), and 0.804 (subjects outside the ICU). The differences between AUROCs are summarized in Table 2. There was a significant difference between the AUROCs of PCT and PCT–qSOFA in all patients. In addition, the AUROCs of qSOFA and PCT–qSOFA were significant even after excluding patients outside the ICU.

4. Post-test probability analysis to define the diagnostic value of PCT–qSOFA

When applied only to patients outside the ICU, the post-test probability (from 0.900 to 0.900) and positive likelihood ratio (from 4.35 to 4.35) did not change with a qSOFA cutoff of 2 (Table 3). When applied to all subjects, PCT–qSOFA improved the post-test probability (from 0.772 to 0.884) and positive likelihood ratio (from 1.59 to 3.55) with a cutoff qSOFA score of 1 (Table 3).

**DISCUSSION**

Sepsis is a severe disease and the primary cause of death from infection [9]. The clinical and biological phenotypes of sepsis depend on the preexisting acute illness, long-standing comorbidities, medication usage, and interventions [10]. Sepsis differs from infection in that it is an aberrant or dysregulated host response and is associated with organ dysfunction [10].

The first definition of sepsis was based on SIRS and it included fever, tachypnea, hyperventilation, and leukocytosis [3]. The newly introduced Sepsis-3 definition that was established in 2016 defined the word “sepsis” as life-threatening organ dysfunction caused by a dysregulated host response to infection [1, 2]. However, the SOFA scoring system showed significant discrepancies when used to distinguish organ failure from infections [11]. It was not easy to differentiate heterogeneous contexts, such as hypovolemia, severe heart failure, or severe pulmonary embolism, from sepsis using SOFA scores [2], and the application of SOFA could delay the detection of sepsis before organ failure occurs.

The current study evaluated the combination of PCT and qSOFA rather than SOFA because evaluating the qSOFA score is easy for
nurses and other medical workers who treat critical patients [1].
PCT is a well-known indicator that is useful for the early confi-
rmation of systemic inflammation and provides guidance for anti-
biotic therapy [4]. There are many other biomarkers for sepsis, such
as C-reactive protein (CRP), lactate, and cytokine levels. However,
the CRP biomarker has a relatively low specificity [4, 12]. Lactate
concentration is inadequate for use as an early indicator, and cy-
tokine levels do not show a significant advantage over PCT in this
respect [4, 12]. Moreover, the application of PCT-qSOFA may be
more convenient if PCT is measured using a point-of-care device
at the bedside [13].

The diagnostic performance of qSOFA alone is not satisfactory.
Therefore, some modifications are needed if qSOFA or PCT is to be
applied for the diagnosis of sepsis. Post-test probability analy-
sis was performed to define the diagnostic value of PCT-qSOFA.
By definition, pretest probability is the probability of the disease
before the test (prevalence, true positive plus false negative/total
sample). In contrast, post-test probability is the probability of the
disease after the test (positive predictive value, true positive/true
positive plus false positive). A qSOFA score was proposed for the
non-ICU setting; an initial retrospective analysis indicated that
qSOFA scores could be a useful clinical tool, especially for physi-
cians and other practitioners working outside the ICU [1, 2]. The
post-test probability of the combination of PCT and qSOFA scores
remained the same after excluding patients in the ICU from the
analysis. However, PCT-qSOFA scores of all patients showed im-
proved post-test probability (from 0.772 to 0.884) and a positive
likelihood ratio (from 1.59 to 3.55), implying that PCT-qSOFA de-
tected 11.2% more sepsis events than qSOFA alone (88.4% vs. 77.2%).

Although this was the first attempt to combine PCT and qSOFA
for the diagnosis of septicemia in Korea, other biomarkers are also
needed to evaluate the diagnostic performance. Although the
qSOFA score is known to be applicable to patients in the ICU, we
attempted to apply it to all patients, including patients in the ICU,
and found that PCT-qSOFA showed meaningful results with the
modification of criteria from the presence of 2 or more qSOFA
points to one.

There has been debate regarding suspicions of the diagnostic
accuracy of SOFA and qSOFA on the basis of the Sepsis-3 defini-
tion [14]. The new definition requires the presence of organ fail-
ure. Additionally, the SIRS criteria have been deleted altogether.
Many heterogeneous contexts (for example hypovolemia, cardiac
failure, and pulmonary embolism) were misdiagnosed as sepsis
with qSOFA. On the contrary, hypoxemia, renal failure, coagula-
tion defects, and hyperbilirubinemia could be missed with qSOFA.
This may be the reason qSOFA was proposed for the non-ICU set-
ting initially. We are of the opinion that PCT responds to systemic
inflammatory response and compensates for qSOFA.

The limitation of this study is that it is a single-center analysis
involving fewer subjects. A multicenter study is needed to secure
more evidence. In conclusion, PCT-qSOFA is useful for evaluat-
ing sepsis in the ICU setting also. We recommend the application
of PCT-qSOFA for the diagnosis of sepsis, regardless of ICU ad-
mission.

요 약

배경: 패혈증은 위중한 환자로 신속하고 정확한 진단이 필요하
다. 이 연구의 목적은 프로칼시토닌(procalcitonin, PCT)과 신속 순
차정기부진평가(quick sequential organ failure assessment, qSOFA)
를 함께 사용하면 패혈증 환자의 진단에 도움이 되는 지에 대해 알
아보는 것이다.

방법: 총 204명의 환자를 혈액배양 결과 및 SIRS 기준(≥2/4) 중족
유무에 따라 세군 패혈증군(N=67), 혈액배양 음성 패혈증군(N=37),
패혈증 그룹과 일치하는 임상 증상이나 잠재가 없는 혈액배양 양
성군(N=35) 및 패혈증의 증가가 없는 대조군(N=65)의 네 개의 군
으로 분류하였다. PCT-qSOFA의 유용성은 사후확률분석으로 평
가하였다.

결과: 중환자실 환자를 포함한 모든 환자들에서 qSOFA와 PCT를
병합하면 사후확률이 0.772에서 0.884로 증가하고, 양성우도비도
1.59에서 3.55로 증가하였다. 하지만 중환자실 환자를 제외한 경우
진단성능의 개선은 보이지 않았다.

결론: 중환자실 환자를 포함한 모든 환자들에서 qSOFA와 PCT를
함께 사용하는 것이 패혈증을 진단하는데 도움이 되었다.

Conflicts of Interest

None declared.

Acknowledgements

This study was funded by a grant from the Korean Society of Di-
agnostic Immunology.
REFERENCES

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315:801-10.
2. Cortés-Puch I and Hartog CS. Opening the debate on the new sepsis definition change is not necessarily progress: revision of the sepsis definition should be based on new scientific insights. Am J Respir Crit Care Med 2016;194:16-8.
3. Simpson SQ. SIRS in the time of Sepsis-3. Chest 2018;153:34-8.
4. Meisner M. Update on procalcitonin measurements. Ann Lab Med 2014;34:263-73.
5. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-32.
6. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
7. Spoto S, Cella E, de Cesaris M, Locorriere L, Mazzaroppi S, Nobile E, et al. Procalcitonin and MR-proadrenomedullin combination with SOFA and qSOFA scores for sepsis diagnosis and prognosis: a diagnostic algorithm. Shock 2018;50:44-52.
8. Kaukonen KM, Bailey M, Pilcher D, Cooper DJ, Bellomo R. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med 2015;372:1629-38.
9. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637.
10. Salomão R, Ferreira BL, Salomão MC, Santos SS, Azevedo LCP, Brunalti MKC, et al. Sepsis: evolving concepts and challenges. Braz J Med Biol Res 2019;52:e8595.
11. Vincent JL, Martin GS, Levy MM. qSOFA does not replace SIRS in the definition of sepsis. Crit Care 2016;20:210.
12. Faix JD. Biomarkers of sepsis. Crit Rev Clin Lab Sci 2013;50:23-36.
13. Singh M and Anand L. Bedside procalcitonin and acute care. Int J Crit Illn Inj Sci 2014;4:233-7.
14. Cortés-Puch I and Hartog CS. Opening the debate on the new sepsis definition change is not necessarily progress: revision of the sepsis definition should be based on new scientific insights. Am J Respir Crit Care Med 2016;194:16-8.